TW202404592A - 用於治療癌症之組合療法 - Google Patents
用於治療癌症之組合療法 Download PDFInfo
- Publication number
- TW202404592A TW202404592A TW112112998A TW112112998A TW202404592A TW 202404592 A TW202404592 A TW 202404592A TW 112112998 A TW112112998 A TW 112112998A TW 112112998 A TW112112998 A TW 112112998A TW 202404592 A TW202404592 A TW 202404592A
- Authority
- TW
- Taiwan
- Prior art keywords
- azd5305
- prostate cancer
- abiraterone acetate
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362614P | 2022-04-07 | 2022-04-07 | |
| US63/362,614 | 2022-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202404592A true TW202404592A (zh) | 2024-02-01 |
Family
ID=86184958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112112998A TW202404592A (zh) | 2022-04-07 | 2023-04-07 | 用於治療癌症之組合療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250228847A1 (https=) |
| EP (1) | EP4504147A1 (https=) |
| JP (1) | JP2025511403A (https=) |
| KR (1) | KR20240170958A (https=) |
| CN (1) | CN118973555A (https=) |
| AU (1) | AU2023250030A1 (https=) |
| CA (1) | CA3254950A1 (https=) |
| IL (1) | IL316019A (https=) |
| MX (1) | MX2024012369A (https=) |
| TW (1) | TW202404592A (https=) |
| WO (1) | WO2023194525A1 (https=) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| WO2018191141A1 (en) * | 2017-04-13 | 2018-10-18 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
-
2023
- 2023-04-06 WO PCT/EP2023/059123 patent/WO2023194525A1/en not_active Ceased
- 2023-04-06 IL IL316019A patent/IL316019A/en unknown
- 2023-04-06 KR KR1020247036945A patent/KR20240170958A/ko active Pending
- 2023-04-06 JP JP2024559036A patent/JP2025511403A/ja active Pending
- 2023-04-06 AU AU2023250030A patent/AU2023250030A1/en active Pending
- 2023-04-06 US US18/853,520 patent/US20250228847A1/en active Pending
- 2023-04-06 CN CN202380032506.8A patent/CN118973555A/zh active Pending
- 2023-04-06 EP EP23719306.5A patent/EP4504147A1/en active Pending
- 2023-04-06 CA CA3254950A patent/CA3254950A1/en active Pending
- 2023-04-07 TW TW112112998A patent/TW202404592A/zh unknown
-
2024
- 2024-10-04 MX MX2024012369A patent/MX2024012369A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118973555A (zh) | 2024-11-15 |
| AU2023250030A1 (en) | 2024-11-07 |
| JP2025511403A (ja) | 2025-04-15 |
| MX2024012369A (es) | 2024-11-08 |
| IL316019A (en) | 2024-11-01 |
| EP4504147A1 (en) | 2025-02-12 |
| KR20240170958A (ko) | 2024-12-05 |
| WO2023194525A1 (en) | 2023-10-12 |
| CA3254950A1 (en) | 2023-10-12 |
| US20250228847A1 (en) | 2025-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7788114B2 (ja) | ヒトにおける固形腫瘍の処置のためのC.novyi | |
| KR20170131491A (ko) | Ras 돌연변이와 관련된 암의 치료 방법 | |
| US20250213556A1 (en) | Combination therapy for treating cancer | |
| TW202404593A (zh) | 用於治療癌症的組合療法 | |
| TW202404592A (zh) | 用於治療癌症之組合療法 | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| KR20260010420A (ko) | 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용 | |
| WO2024088192A1 (en) | An aurora a inhibitor for use in treatments of cancers | |
| US20250170146A1 (en) | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations | |
| CN117794544A (zh) | 实体瘤治疗用医药组合物 | |
| CN116600804A (zh) | 用于治疗雄激素受体突变的前列腺癌的ezh2抑制疗法 |